Type 2 Diabetes is a long-term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Diabetic kidney disease or DKD, is one of the most frequent microvascular complications of diabetes and is the leading cause of end-stage kidney disease worldwide.

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

https://clinicaltrials.gov/ct2/show/NCT02545049?term=Bayer+17530&rank=1

Trial Information

Start Date17 September 2015
End Date27 February 2020
Trial Duration3.5 - 4 years
Number of Visits16+
Lead CRCAdam Pawluch
StatusOn-Going

For additional information
on this trial contact:

Phone705-566-0005